Stephen Hunger, MD from Children’s Hospital of Philadelphia discusses phase 2 trial of Dasatinib with Philadelphia Chromosome+ ALL and how the results were similar to studies with imatnib at the 2017 American Society of Hematology.
Phase 2 Trial of Dasatinib with Philadelphia Chromosome+ ALL – Results were similar to studies with imatnib
